Centene Corporation

Centene Corporation (CNC) Market Cap

Centene Corporation has a market capitalization of $18.76B.

Financials based on reported quarter end 2025-12-31

Price: $38.16

β–Ό -0.84 (-2.17%)

Market Cap: 18.76B

NYSE Β· time unavailable

CEO: Sarah London

Sector: Healthcare

Industry: Medical - Healthcare Plans

IPO Date: 2001-12-13

Website: https://www.centene.com

Centene Corporation (CNC) - Company Information

Market Cap: 18.76B Β· Sector: Healthcare

Centene Corporation operates as a multi-national healthcare enterprise that provides programs and services to under-insured and uninsured individuals in the United States. Its Managed Care segment offers health plan coverage to individuals through government subsidized programs, including Medicaid, the State children's health insurance program, long-term services and support, foster care, and medicare-medicaid plans, which cover dually eligible individuals, as well as aged, blind, or disabled programs. Its health plans include primary and specialty physician care, inpatient and outpatient hospital care, emergency and urgent care, prenatal care, laboratory and X-ray, home-based primary care, transportation assistance, vision care, dental care, telehealth, immunization, specialty pharmacy, therapy, social work, nurse advisory, and care coordination services, as well as prescriptions and limited over-the-counter drugs, medical equipment, and behavioral health and abuse services. This segment also offers various individual, small group, and large group commercial healthcare products to employers and directly to members. The company's Specialty Services segment provides pharmacy benefits management services; nurse advice line and after-hours support services; vision and dental services, as well as staffing services to correctional systems and other government agencies; and services to Military Health System eligible beneficiaries. This segment offers its services and products to state programs, correctional facilities, healthcare organizations, employer groups, and other commercial organizations. The company provides its services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in St. Louis, Missouri.

Analyst Sentiment

57%
Buy

Based on 21 ratings

Analyst 1Y Forecast: $43.22

Average target (based on 5 sources)

Consensus Price Target

Low

$38

Median

$44

High

$59

Average

$46

Potential Upside: 19.7%

Price & Moving Averages

Loading chart...

πŸ“˜ Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

πŸ“˜ Centene Corporation (CNC) β€” Investment Overview

🧩 Business Model Overview

Centene Corporation is a diversified managed care organization focused primarily on government-sponsored healthcare programs. Its core offerings center on providing managed health care services to individuals enrolled in Medicaid, Medicare, and the Health Insurance Marketplace, positioning itself as a key intermediary in the U.S. healthcare safety net. In addition to serving low-income populations, seniors, and military families, Centene supports state and federal agencies with administrative solutions, coverage facilitation, and care management services. The company operates in all 50 U.S. states, engaging a broad network of providers, hospitals, and specialty health partners, with a significant emphasis on local, community-based care delivery.

πŸ’° Revenue Model & Ecosystem

Centene generates revenue primarily from contracts with state and federal governments to provide managed care services for Medicaid and Medicare beneficiaries. The company receives per-member, per-month fees for administering healthcare coverage and coordinating benefits, effectively making the bulk of its revenue recurring and subscription-like in nature. Additional streams include specialty services such as pharmacy benefit management, behavioral health, telehealth, vision, dental, and correctional facility healthcare, which together form a comprehensive healthcare ecosystem targeting public-sector populations. Centene also operates in the commercial Health Insurance Marketplace, offering individual and small group plans. The interplay between government programs, commercial offerings, and auxiliary healthcare services creates network effects and cross-selling opportunities within the healthcare value chain.

🧠 Competitive Advantages

  • Brand strength: Established reputation as a leading government healthcare partner with recognized expertise in complex, high-need populations.
  • Switching costs: Deep integration with state and federal healthcare systems raises operational hurdles for clients to switch administrators, supporting strong retention.
  • Ecosystem stickiness: Broad portfolio of specialty services, from pharmacy management to behavioral health, increases reliance by agencies and participants on Centene's integrated solutions.
  • Scale + supply chain leverage: Nationwide network, large membership base, and consolidated purchasing power allow Centene to negotiate favorable provider contracts and optimize administrative efficiency.

πŸš€ Growth Drivers Ahead

Centene’s forward growth trajectory is supported by several strategic catalysts. The ongoing expansion of Medicaid and Medicare populations, driven by demographic trends and policy initiatives, underpins a growing addressable market. Centene is also poised to benefit from state Medicaid contract wins, expansion into new geographies, and increased penetration in the Health Insurance Marketplace. Active investment in care management, digital health solutions, and specialty pharmacy aims to improve health outcomes and cost efficiency, further differentiating its offering. Strategic acquisitions and partnerships have expanded Centene's reach into adjacent verticals, including behavioral health and specialty care, creating new pathways for revenue growth and service innovation.

⚠ Risk Factors to Monitor

Centene faces risks from competitive pressures in both public and private health plan administration, with industry consolidation and the entry of technology-driven disruptors creating uncertainty. Regulatory risks are significant, as government reimbursement rates, eligibility rules, and policy shifts can materially impact operations and profitability. Margin pressure can emerge from rising medical costs, regulatory caps, and challenges in managing complex populations. The business is also exposed to operational risks related to large-scale contract integrations, technology modernization, and compliance requirements. Lastly, evolving healthcare models and changing consumer expectations may drive rapid shifts in demand for managed care solutions.

πŸ“Š Valuation Perspective

Centene is typically valued by the market as a leading player among managed care organizations with a public-sector focus. Compared to private-sector insurers or diversified health services companies, Centene’s valuation often reflects a balance between growth potential from expanding public programs and the perceived risk inherent to regulatory exposure. The company can trade at a premium in periods of robust government healthcare expansion or successful strategic execution, but also at a discount relative to peers during times of heightened policy risk or operational headwinds.

πŸ” Investment Takeaway

Centene Corporation offers exposure to the defensive, steadily growing sector of government-sponsored managed healthcare. The company's scale, diversified service offering, and strong positioning in Medicaid and Medicare administration create substantial barriers to entry and opportunities for sustainable revenue growth. However, investors must balance these strengths against notable risks tied to government policy shifts, ongoing margin pressures, and potential for competitive disruption. While Centene's focus on public programs and specialty services positions it well for long-term secular trends, careful monitoring of regulatory dynamics and operational execution remains crucial for investment success.


⚠ AI-generated research summary β€” not financial advice. Validate using official filings & independent analysis.

Centene closed a difficult 2025 slightly ahead of expectations, with Medicaid HBR improvement and solid Medicare performance offset by Marketplace NSA-related costs and out-of-period items. Management guided to >$3 adjusted EPS in 2026 (>40% growth), driven by stable Medicaid margins, significant Marketplace margin recovery, and continued progress in Medicare Advantage toward 2027 breakeven. While policy and rate uncertainties (NSA, ACA risk adjustment, MA rates) persist, execution, pricing, and operational initiatives, including anti-fraud efforts and AI deployment, underpin a cautiously constructive outlook.

Growth

  • Guides 2026 adjusted EPS to >$3 (>40% YoY growth)
  • Expect meaningful Marketplace pretax margin expansion in 2026 vs. ~-1% in 2025
  • Medicare Part D enrollment tracking to high single-digit % growth by end of Q1 2026 vs. YE 2025
  • Continued progress toward breakeven Medicare Advantage in 2027

Business Development

  • Signed definitive agreement to divest remaining Magellan business (Q4 GAAP impact: $389M net loss)
  • Collaborated with Wakely on an industry report to improve ACA risk-adjustment visibility
  • Launched redesigned dual-eligibles operating model within Medicare Advantage

Financials

  • 2025 premium and service revenue: $174.6B
  • Q4 adjusted diluted loss per share: -$1.19; full-year 2025 adjusted diluted EPS: $2.08
  • Q4 GAAP diluted loss per share: -$2.24 (includes $389M loss tied to Magellan divestiture agreement)
  • Medicaid Q4 HBR: 93% (40 bps q/q improvement; 190 bps better vs. Q2)
  • 2025 composite Medicaid rates ~+5.5% vs. 2024; 1/1/26 rates in line
  • 2026 Medicaid assumptions: stable HBR; net rate impact mid-4%; net trend mid-4%
  • Marketplace Q4 HBR ~100 bps above plan due to 2023 CMS reconciliation and added NSA accruals; underlying trend slightly better than expected
  • Marketplace lost ~1% pretax margin in 2025; 2026 pricing expected to capture market shifts/policy changes
  • Medicaid membership ended 2025 at ~12.5M
  • Ambetter membership expected ~3.5M at Q1 2026-end vs. ~5.0M in Dec 2025
  • Anticipates a meaningful payable position for 2026 ACA risk adjustment

Capital & Funding

  • Portfolio simplification via divestiture of remaining Magellan business; prior Magellan Pharmacy and specialty assets had been sold at gains
  • No additional share repurchase/dividend/debt updates discussed in prepared remarks

Operations & Strategy

  • Medicaid focus: network optimization, enhanced clinical programs, rate advocacy, collaboration on program reform, tighter utilization management, and more aggressive provider fraud actions
  • Established ABA task force; narrowed to evidence-based providers; member/provider engagement to improve outcomes and costs
  • Proactive NSA stance including litigation; filed multimillion-dollar suit against a NY provider alleging claim manipulation
  • Marketplace execution through dynamic open enrollment; mix shifting toward bronze plans (>30% of 2026 members)
  • Expanded use of AI/analytics (e.g., 75 fraud-scoring algorithms; faster prior auths; improved call centers; enhanced payment integrity)
  • Medicare: emphasis on STARS, clinical engagement, SG&A efficiency; refining MA footprint to improve profitability

Market & Outlook

  • 2026 outlook assumes Medicaid margin stability, significant Marketplace margin recovery, and continued MA improvement toward 2027 breakeven
  • Post-expiration of enhanced APTCs incorporated into 2026 pricing; paid membership pacing aligns with expectations
  • Expect planned Q1 2026 MA membership decline; PDP growing high single digits
  • Initial 2027 MA advance notice suggests rate pressure; final rates expected in early April
  • Management expects ongoing policy-related variability; reflected prudently in 2026 guidance

Risks Or Headwinds

  • Elevated Medicaid costs in behavioral health, home health, and high-cost drugs
  • No Surprises Act disputes/IDR process driving higher costs and accruals
  • ACA risk adjustment uncertainty (expects payable position for 2026 plan year)
  • Expiration of enhanced APTCs impacting Marketplace risk pool and paid rates
  • Potential Medicare Advantage rate pressure for 2027 per initial advance notice
  • Ongoing Medicaid membership attrition

Sentiment: MIXED

Note: This summary was synthesized by AI from the CNC Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"For the quarter ending December 31, 2025, CNC posted revenue of $49.73 billion with a net loss of $1.1 billion, translating to an EPS of -$2.24. The company generated a free cash flow of $224 million, with an operating cash flow of $437 million. The company's financial position saw total assets of $76.75 billion against liabilities of $56.69 billion. Net debt stood at -$487 million, highlighting a cash surplus. Revenue grew modestly with stable drivers in its primary segments. Profitability is a concern given the negative EPS and net margin. Cash flow quality remains strong with positive FCF indicating liquidity, despite low shareholder returns as no dividend was paid and limited share buybacks occurred. The balance sheet reflects a strong position with negative net debt, suggesting sound financial resilience. Valuation could seem attractive, yet profitability issues linger, as reflected in cautious analyst sentiment with a consensus price target of $45.67. While providing growth potential, improved profitability will be key to enhancing investor confidence and returns."

Revenue Growth

Neutral

Revenue grew to $49.73 billion, indicating stable growth. The primary drivers remain steady.

Profitability

Neutral

The company posted a net loss with an EPS of -$2.24. Negative margins impact profitability metrics.

Cash Flow Quality

Positive

Positive free cash flow of $224 million shows strong liquidity, though dividend and buyback activity is minimal.

Leverage & Balance Sheet

Good

The balance sheet is robust with net debt at -$487 million, indicating no immediate financial distress.

Shareholder Returns

Caution

Limited shareholder returns with no dividends and minor buybacks.

Analyst Sentiment & Valuation

Caution

Analyst sentiment is cautious with a consensus target of $45.67, implying concerns over profitability.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
πŸ“

SEC Filings (CNC)

Β© 2026 Stock Market Info β€” Centene Corporation (CNC) Financial Profile